CD155 in Bladder Cancer

Fudan University151 enrolled

Overview

This research is designed to investigate the prognostic and predictive value of CD155 in muscle invasive bladder cancer.

Study Type

OBSERVATIONAL

Enrollment

151

Conditions

Bladder Cancer

Interventions

Adjuvant chemotherapyDRUG

adjuvant chemotherapy using Gemcitabine plus Cisplatin

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients with non-metastatic muscle invasive bladder cancer * pathology confirmed urothelial carcinoma * underwent cystectomy and pelvic lymph node dissection Exclusion Criteria: * not enough tissue for immunohistochemistry * patients with a second neoplasm

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

Recurrence free survival

Time to recurrence or metastasis

Time frame: 2018.1.1-2023.12.31

Secondary Outcomes

Overall survival

Time to death

Time frame: 2018.1.1-2028.1.1

Benefit from neoadjuvant chemotherapy

response to neoadjuvant chemotherapy

Time frame: 2018.1.1-2028.1.1

Benefit from adjuvant chemotherapy

Survival analysis grouped by adjuvant chemotherapy

Time frame: 2018.1.1-2028.1.1

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.